AlphAIAlphAI — Financial news for AI agents
mugglehead.comOCT 252 min read$GMAB

Genmab reports 75% response in colorectal cancer study

Genmab reported 75% response rate in metastatic colorectal cancer study, 67% in second-line. Data includes unconfirmed responses, with full details pending. The company's U.S. shares closed at $43.79 on Oct. 23. Genmab plans an investor update on Oct. 28.

Original reporting
mugglehead.com
Published Oct 25, 2026, 11:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 12:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Genmab reports 75% response in colorectal cancer study — source image
Source · mugglehead.com
Decision brief

The 30-second read

$GMABBullishMed
01

Why it matters

The 75% response rate is a strong early signal, but the study is uncontrolled and lacks confirmed response duration, leaving uncertainty about true efficacy.

02

Market read

The announcement provides fresh clinical data that could move GMAB stock, though the impact may be muted pending further confirmation.

03

What to watch

Upcoming investor update on Oct 28 could clarify durability and Phase 3 timeline, which may swing sentiment.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Genmab (NASDAQ:GMAB) is a Copenhagen‑based biotech developing antibody therapies. The company released new Phase 2 data for petosemtamab in metastatic colorectal cancer.

Company-level read

Ticker impact

$GMABBullishMedium confidence
Context

Genmab disclosed Phase 2 data showing a 75% tumor response rate in metastatic colorectal cancer, a new clinical update not previously reported.

Expected impact

potential upward pressure as the market prices in the encouraging response rate, tempered by caution over limited data.

Evidence & confidence

The response rate is high for a Phase 2 study, but absence of confirmed duration and control data limits conviction.

Market effects

Sector

Biotech sector may see modest uplift as investors reassess EGFR/LGR5‑targeted approaches.

Regional

European biotech markets could benefit given Genmab's Copenhagen base.

Global

Limited to biotech investors; no broad market impact.

Counterpoint

What could challenge this read

Skeptics may short GMAB due to lack of confirmatory data, no control arm, and potential safety concerns.

Key entities

  • company
    Genmab A/S

    Biotech firm reporting the Phase 2 results.

  • company
    Incyte Corporation

    Partner in a separate KRAS‑targeted colorectal trial.

Read at source← All news

StoryGenmab reports 75% and 67% objective response rates in Phase 2 colorectal cancer trial

Also covered by

2 outlets

Related articles

OCT 25
$GMABHighAI 9/10

Genmab A/S: Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Genmab (GMAB) reported updated Phase 2 trial results for petosemtamab in metastatic colorectal cancer, showing 75% and 67% objective response rates in first- and second-line settings, respectively. The data supports ongoing Phase 3 trials and was presented at ESMO Congress 2026. Petosemtamab is an investigational bispecific antibody targeting EGFR and LGR5.

finanznachrichten.de3 min
OCT 25
$GMABMedAI 8/10

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study o

Genmab (GMAB) reported updated Phase 2 trial data for petosemtamab, showing 75% and 67% objective response rates in 1L and 2L mCRC patients, respectively. The study, presented at ESMO 2026, supports ongoing Phase 3 trials. Petosemtamab, targeting EGFR and LGR5, is being evaluated in multiple solid tumors. Genmab will host an investor update on October 28.

gurufocus.com2 min
OCT 25
$GMABMedAI 8/10

Genmab reports phase 2 trial data for colorectal cancer drug

Genmab (NASDAQ:GMAB) reported Phase 2 trial data for petosemtamab in metastatic colorectal cancer, showing 75% and 67% response rates in first- and second-line patients, respectively. The trial involved 79 patients and was presented at the European Society for Medical Oncology Congress 2026. Genmab is conducting four Phase 3 trials and will host an investor update.

investing.com2 min
OCT 25
$GMABMedAI 8/10

Genmab A/S (GMAB) Reports 75%/67% ORR in Phase 2 mCRC

Genmab reported updated Phase 2 data for petosemtamab plus chemo in metastatic colorectal cancer, showing 75% ORR in 1L and 67% in 2L, with 81% in 1L left-sided tumors. Median follow-up was 5.9 and 7.1 months. Most responses were confirmed. This update supports Genmab’s shift into late-stage GI oncology.

tradingview.com2 min
OCT 24
$GMABMed

Genmab and Incyte agree to colorectal cancer trial

Genmab and Incyte will collaborate on a Phase 1/2 trial combining Genmab's petosemtamab with Incyte's INCB161734 and chemotherapy for first-line colorectal cancer with KRAS G12D mutation. Genmab will lead the study, with Incyte co-funding and supplying its drug. Both companies' shares closed at $43.79 and $115.71 respectively before the announcement.

mugglehead.com2 min